T. Masszi

发表

Ten-Year Remission of Psoriasis after Allogeneic but Not Autologous Bone Marrow Transplantation

L. Kemény, T. Masszi, Á. Farkas, 2005, Dermatology.

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.

J. Cortes, R. Mesa, A. Vannucchi, 2015, JAMA oncology.

Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.

M. Beksac, A. Palumbo, P. Sonneveld, 2016 .

An Alu‐mediated novel large deletion is the most frequent cause of type 3 von Willebrand disease in Hungary

R. Marschalek, T. Masszi, R. Schneppenheim, 2008, Journal of thrombosis and haemostasis : JTH.

Analyses of donor-derived keratinocytes in hairy and nonhairy skin biopsies of female patients following allogeneic male bone marrow transplantation.

É. Mezey, K. Németh, T. Masszi, 2012, Stem cells and development.

The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma

A. Tordai, T. Masszi, P. Reményi, 2018, Leukemia & lymphoma.

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

J. Radich, H. Kantarjian, A. Countouriotis, 2007, Blood.

myeloid leukemia in patients 70 years or older care, including hydroxyurea, in the treatment of newly diagnosed acute A randomized phase 3 study of tipifarnib compared with best supportive

W. Jędrzejczak, H. Dombret, L. Möllgård, 2011 .

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.

W. Jędrzejczak, H. Dombret, G. Martinelli, 2007, Blood.

Complement Levels at Admission Reflecting Progression to Severe Acute Kidney Injury (AKI) in Coronavirus Disease 2019 (COVID-19): A Multicenter Prospective Cohort Study

G. Lippi, Z. Prohászka, L. Cervenak, 2022, Frontiers in Medicine.

Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.

C. Hemmelmann, J. Finke, T. Luft, 2019, The Lancet. Haematology.

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

T. Brümmendorf, E. Vellenga, H. Kantarjian, 2014, American journal of hematology.

D. Cella, T. Masszi, Dong-Wook Kim, 2012, Leukemia research.

Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms.

L. Reiniger, T. Masszi, C. Bödör, 2019, Pathology.

Changes in quality of life and disease‐related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy

M. Griesshammer, S. Verstovsek, R. Mesa, 2016, European journal of haematology.

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations

A. Tordai, T. Masszi, P. Reményi, 2014, Haematologica.

[Complex molecular genetic algorithm in the diagnosis of myeloproliferative neoplasms].

A. Tordai, T. Masszi, P. Reményi, 2014, Orvosi hetilap.

HFE C282Y Mutation as a Genetic Modifier Influencing Disease Susceptibility for Chronic Myeloproliferative Disease

A. Tordai, T. Masszi, S. Lueff, 2009, Cancer Epidemiology Biomarkers & Prevention.

[Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].

A. Tordai, T. Masszi, S. Lueff, 2007, Orvosi hetilap.

Serum fetuin-A level is independent of Helicobacter pylori postinfection status in systemic lupus erythematosus.

L. Kalabay, H. Farkas, Z. Prohászka, 2022, Acta microbiologica et immunologica Hungarica.

Insights on Multiple Myeloma Treatment Strategies

M. Beksac, H. Goldschmidt, M. Dimopoulos, 2018, HemaSphere.

VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.

M. Dimopoulos, P. Richardson, H. van de Velde, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

A. Nademanee, P. Stiff, V. Bachanova, 2015, The Lancet.

c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma

D. Esseltine, P. Ganly, J. Keats, 2020, European journal of haematology.

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia

B. Pégourié, S. Iacobelli, G. Gahrton, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multiple Myeloma Treatment in Real‐world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Jesús Martín Sánchez, M. Beksac, H. Goldschmidt, 2018, Clinical lymphoma, myeloma & leukemia.

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial

J. Radich, F. Giles, G. Saglio, 2021, Leukemia.

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

M. Dimopoulos, A. Palumbo, A. Jakubowiak, 2017, British journal of haematology.

Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers

Á. Illés, T. Masszi, G. Mikala, 2022, Pathology & Oncology Research.

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

W. Wiktor-Jedrzejczak, F. Giles, G. Saglio, 2017, Leukemia.

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

W. Wiktor-Jedrzejczak, T. Brümmendorf, M. Baccarani, 2015, Leukemia.

Effectiveness of intra-arterial steroid administration for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease.

V. Bérczi, T. Masszi, P. Reményi, 2019, Clinical radiology.

M. Dimopoulos, A. Palumbo, A. Jakubowiak, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Apoptosis induction by retinoids in eosinophilic leukemia cells: implication of retinoic acid receptor-alpha signaling in all-trans-retinoic acid hypersensitivity.

C. Chomienne, T. Masszi, L. Delva, 2006, Cancer research.

Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation

A. Zander, C. Crawley, J. Passweg, 2008, Haematologica.

Combined effect of pancreatic lipid content and gene variants (TCF7L2, WFS1 and 11BHSD1) on B-cell function in Middle Aged Women in a Post Hoc Analysis

P. Igaz, A. Patócs, A. Somogyi, 2022, Diabetology & Metabolic Syndrome.

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

Michael L. Wang, M. Dimopoulos, A. Palumbo, 2016, Blood.

Analysis of platelet α2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy

I. Préda, R. Kiss, T. Masszi, 2008, Thrombosis and Haemostasis.

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

M. Dimopoulos, A. Palumbo, D. Rossi, 2016, Leukemia.

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment

A. Palumbo, A. Jakubowiak, D. Siegel, 2017, Blood cancer journal.

Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA

C. Scheid, T. Masszi, A. Rahemtulla, 2012, Bone Marrow Transplantation.

Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers

Z. Lengyel, Á. Illés, Z. Borbényi, 2021, Pathology & Oncology Research.

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.

D. Esseltine, P. Ganly, P. Richardson, 2017, Blood.

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.

A. Nademanee, P. Stiff, V. Bachanova, 2018, Blood.

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

M. Griesshammer, S. Verstovsek, R. Mesa, 2015, The New England journal of medicine.

Cardiac Amyloidosis with Normal Wall Thickness: Prevalence, Clinical Characteristics and Outcome in a Retrospective Analysis

R. Sepp, T. Masszi, A. Nagy, 2022, Biomedicines.

Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial.

K. Savage, P. Zinzani, S. Horwitz, 2013 .

Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and

M. Labopin, I. Yakoub-Agha, H. Sengeløv, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

M. Dimopoulos, K. Konstantopoulos, M. Mohty, 2021, The Lancet.

[How long does a myeloma patient currently wait for the diagnosis in Hungary?].

T. Masszi, H. Andrikovics, G. Mikala, 2014, Orvosi hetilap.

Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia

A. Tordai, L. Kalmár, T. Masszi, 2012, Medical Oncology.

Decreased Plasma Level of Cytokeratin 20 (KRT20) Is Indicative of the Emergence and Severity of Acute GvHD Irrespective to the Type of Organ Involvement

E. Buzás, A. Lakshmanan, T. Masszi, 2022, Biomedicines.

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.

M. Griesshammer, S. Verstovsek, M. Hino, 2020, The Lancet. Haematology.

Investigation of TGFB1 −1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation

A. Tordai, J. Sinko, T. Masszi, 2019, Bone Marrow Transplantation.

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

M. Cazzola, M. Griesshammer, S. Verstovsek, 2016, Haematologica.

Patient‐reported health‐related quality of life from the phase III TOURMALINE‐MM1 study of ixazomib‐lenalidomide‐dexamethasone versus placebo‐lenalidomide‐dexamethasone in relapsed/refractory multiple myeloma

C. Cleeland, P. Richardson, P. Moreau, 2018, American journal of hematology.

Early Versus Delayed Autologous Stem Cell Transplantation and Interferon Maintenance in Multiple Myeloma: Single-Center Experience of 18 Years.

T. Masszi, P. Reményi, Á. Bátai, 2016, Transplantation proceedings.

Variant Transthyretin Amyloidosis (ATTRv) in Hungary: First Data on Epidemiology and Clinical Features

B. Iványi, Á. Szilágyi, Beáta Csányi, 2021, Genes.

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

P. Richardson, H. van de Velde, A. Di Bacco, 2017, Haematologica.

Donor KIR2DS1 reduces the risk of transplant related mortality in HLA-C2 positive young recipients with hematological malignancies treated by myeloablative conditioning

A. Tordai, T. Masszi, P. Reményi, 2019, PloS one.

Characterization and Function of Histamine Receptors in Human Bone Marrow Stromal Cells

A. Falus, E. Buzás, É. Mezey, 2012, Stem cells.

Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years

W. Wiktor-Jedrzejczak, M. Labopin, K. Indrák, 2009, Annals of Hematology.

Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study)

Á. Illés, H. Losonczy, Z. Borbényi, 2018, Pathology & Oncology Research.

Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort

A. Tordai, T. Masszi, P. Reményi, 2014, Leukemia & lymphoma.

Haematopoietic Stem Cell Transplantation in MDS for Adults

T. Masszi, 2011 .

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies

M. Griesshammer, S. Verstovsek, P. Guglielmelli, 2018, Annals of Hematology.

leukemia after failure of first-line imatinib: a randomized phase 2 trial Dasatinib or high-dose imatinib for chronic-phase chronic myeloid

J. Radich, P. Rousselot, T. Robak, 2008 .

Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT.

M. Labopin, A. Nagler, M. Mohty, 2018, European journal of cancer.

Additional Chromosome Abnormalities, BCR-ABL Tyrosine Kinase Domain Mutations and Clinical Outcome in Hungarian Tyrosine Kinase Inhibitor-Resistant Chronic Myelogenous Leukemia Patients

A. Tordai, G. Ujj, T. Masszi, 2011, Acta Haematologica.

Updated Efficacy and Safety Data From the AETHERA Trial of Consolidation With Brentuximab Vedotin After Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse.

P. Stiff, V. Bachanova, T. Masszi, 2016, Clinical advances in hematology & oncology : H&O.

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

A. Nademanee, P. Stiff, V. Bachanova, 2015 .

An EBMT Prospective Non-Interventional Study of Outcomes and Toxicity of Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second Generation Tyrosine Kinase Inhibitors

A. Ganser, N. Kröger, S. Iacobelli, 2016 .

Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors

M. Baccarani, J. Cortes, H. Khoury, 2015, Leukemia & lymphoma.

Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Chronic Myeloid Leukemia in Blast Phase (CML-BP): 2-Year Data from CA180-035

H. Dombret, H. Kantarjian, G. Saglio, 2008 .

Secondary ALK negative anaplastic large cell lymphoma in a patient with lymphomatoid papulosis of 40 years duration.

T. Masszi, Á. Bátai, J. Fodor, 2010, The American Journal of dermatopathology.

Sex-specific survival difference in association with HLA-DRB1∗04 following allogeneic haematopoietic stem cell transplantation for lymphoid malignancies.

A. Tordai, T. Masszi, P. Reményi, 2018, Human immunology.

Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial

T. Robak, T. Masszi, K. Sail, 2021, Leukemia & lymphoma.

A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

M. Dimopoulos, J. Cavenagh, H. van de Velde, 2015, American journal of hematology.

The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

P. Stiff, V. Bachanova, T. Masszi, 2014 .

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide

M. Griesshammer, S. Verstovsek, P. Guglielmelli, 2018, British journal of haematology.

Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea

M. Griesshammer, S. Verstovsek, C. Harrison, 2013 .

JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia

A. Tordai, T. Masszi, S. Lueff, 2010, Leukemia.

Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis

A. Vannucchi, A. Tefferi, C. Harrison, 2021, British journal of haematology.

Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group

P. Richardson, F. Baron, I. Yakoub-Agha, 2019, Bone Marrow Transplantation.

Radioguided lymph node biopsy of a chemoresistant lymph node detected on interim FDG PET-CT in Hodgkin lymphoma

V. Bérczi, T. Masszi, I. Garai, 2011, International journal of hematology.

Myelodysplasia and Multiple Myeloma or Monoclonal Gammopathy. A Non-Fortuitous Coexistence

T. Masszi, G. Tarkovács, J. Csomor, 2007 .

Safe and Effective Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) and Low Baseline Platelet Counts with Belinostat

K. Savage, P. Zinzani, S. Horwitz, 2014 .

belinostat In Relapsed Or Refractory Peripheral T-cell Lymphoma (r/r Ptcl) Subtype Angioimmunoblastic T-cell Lymphoma (aitl): Results From The Pivotal Belief Trial : 153

P. Zinzani, S. Horwitz, O. O’Connor, 2013 .

Familial multiple myeloma. Two more families

T. Masszi, P. Farkas, K. Rajczy, 2009 .

Syngeneic transplantation in multiple myeloma – a case-matched comparison with autologous and allogeneic transplantation

G. Gahrton, A. Gratwohl, J. Reiffers, 1999, Bone Marrow Transplantation.

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

P. Sonneveld, A. Chanan-Khan, A. Nooka, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.

M. Dimopoulos, P. Sonneveld, P. Richardson, 2022, The Lancet. Haematology.

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

P. Sonneveld, A. Chanan-Khan, H. Avet-Loiseau, 2020, Journal of Hematology & Oncology.

Accelerated clearance alone explains ultra‐large multimers in von Willebrand disease Vicenza

I. Deák, T. Masszi, A. Gézsi, 2010, Journal of thrombosis and haemostasis : JTH.

The potential role of HLA-DRB1*11 in the development and outcome of haematopoietic stem cell transplantation-associated thrombotic microangiopathy

A. Tordai, T. Masszi, P. Reményi, 2015, Bone Marrow Transplantation.

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

D. Esseltine, H. Einsele, S. Lonial, 2017, British journal of haematology.

Invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients: an autopsy‐driven survey

J. Sinko, T. Masszi, P. Reményi, 2008, Transplant infectious disease : an official journal of the Transplantation Society.

[Gram-negative bacteremia in neutropenic patients with hematologic disorders. Experiences with prophylactic use of fluoroquinolones].

J. Sinko, T. Masszi, V. Cser, 2011, Orvosi hetilap.

Common large partial VWF gene deletion does not cause alloantibody formation in the Hungarian type 3 von Willebrand disease population

H. Losonczy, L. Nemes, T. Masszi, 2011, Journal of thrombosis and haemostasis : JTH.

Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation

M. Abecassis, P. Richardson, F. Baron, 2016, Bone Marrow Transplantation.

Combined Immunosuppression for Acquired Hemophilia A: CyDRi is a Highly Effective Low Toxicity Regimen.

T. Masszi, R. Horvath, M. Gaddh, 2022, Blood.

Low-Dose Combined Immunosuppression Results In Rapid Remission In Patients With Acquired Hemophilia A

K. Pap, T. Masszi, K. Szabó, 2013 .

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

J. Radich, F. Giles, G. Saglio, 2018, Journal of Cancer Research and Clinical Oncology.

Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.

P. Venugopal, D. Neuberg, M. Tallman, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation

A. Tordai, T. Masszi, P. Reményi, 2017, Leukemia & lymphoma.

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

M. Griesshammer, S. Verstovsek, M. Hino, 2018, Blood.

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

M. Griesshammer, S. Verstovsek, M. Hino, 2017 .

Persistent long-term human herpesvirus 6 (HHV-6) infection in a patient with langerhans cell histiocytosis

A. Tordai, J. Jákó, G. Berencsi, 2008, Pathology & Oncology Research.

Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

J. Leonard, F. d'Amore, K. Venkatakrishnan, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

A. Palumbo, P. Sonneveld, A. Chanan-Khan, 2016, The New England journal of medicine.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

A. Palumbo, A. Hui, P. Ganly, 2016, The New England journal of medicine.

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT

N. Kröger, S. Iacobelli, C. Crawley, 2018, Haematologica.

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.

K. Savage, S. Horwitz, L. F. Allen, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma

N. Nagy, D. Alpár, T. Masszi, 2020, Genes.

The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia

A. Tordai, J. Sinko, T. Masszi, 2011, Haematologica.

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Michael L. Wang, M. Dimopoulos, A. Palumbo, 2015, The New England journal of medicine.

Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100

A. Tordai, T. Masszi, P. Reményi, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia

A. Tordai, T. Masszi, Á. Bátai, 2013, Leukemia & lymphoma.

Location and type of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia

A. Tordai, T. Masszi, Á. Bátai, 2013 .

Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT)

M. Abecassis, P. Richardson, F. Baron, 2015, Bone Marrow Transplantation.

Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia

A. Tordai, T. Masszi, H. Andrikovics, 2016, Pathology & Oncology Research.

Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new, non-myeloablative drug combination

T. Masszi, P. Reményi, E. Kelemen, 1998, Bone Marrow Transplantation.

Anti‐thymocyte globulin improves survival free from relapse and graft‐versus‐host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia‐negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT

M. Labopin, D. Blaise, A. Nagler, 2018, Cancer.

Dasatinib in imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia in blast phase after 2 years of follow‐up in a phase 3 study

H. Dombret, J. Cortes, R. Paquette, 2010, Cancer.

Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.

R. Greil, R. Hájek, B. Paiva, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Peripheral Blood Stem Cell Mobilization and Engraftment after Autologous Stem Cell Transplantation with Biosimilar rhG-CSF

Z. Borbényi, T. Masszi, P. Reményi, 2014, Advances in Therapy.

[Allogeneic hematopoietic stem cell transplantation in Hungary].

A. Tordai, T. Masszi, P. Reményi, 2017, Orvosi hetilap.

Remarkably Reduced Transplant-Related Complications by Dibromomannitol Non-Myeloablative Conditioning before Allogeneic Bone Marrow Transplantation in Chronic Myeloid Leukemia

T. Masszi, P. Reményi, Á. Bátai, 2001, Acta Haematologica.

Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor

S. Montoto, N. Russell, E. Jantunen, 2019, Bone Marrow Transplantation.

Bone marrow transplantation in non-malignant disorders.

T. Masszi, P. Reményi, G. Kriván, 1998, Bone marrow transplantation.

Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection

Z. Prohászka, L. Cervenak, T. Masszi, 2021, Frontiers in Immunology.

Long-term treatment-free remission (TFR) following frontline (1L) nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom 144-wk results.

J. Radich, S. Acharyya, F. Giles, 2018 .

Attitudes and Perceptions of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Toward Treatment-Free Remission (TFR)

T. Masszi, K. Benjamin, T. Szczudlo, 2014 .

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2016, The Lancet. Oncology.

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

P. Sonneveld, A. Chanan-Khan, H. Avet-Loiseau, 2018, Haematologica.

[Appearing of bone marrow derived stem cells in healthy and regenerating colonic epithelium].

B. Molnár, F. Sipos, Z. Tulassay, 2009, Orvosi hetilap.

Multiple Myeloma of the Central Nervous System: 13 Cases and Review of the Literature

T. Masszi, G. Mikala, P. Farkas, 2018, Journal of oncology.

Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation

B. Pégourié, S. Iacobelli, G. Gahrton, 2010 .

Bortezomib–Melphalan–Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study.

M. Dimopoulos, J. Miguel, P. Richardson, 2008 .

Screening and monitoring of the BTKC481S mutation in a real‐world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy

P. Csermely, L. Gergely, E. Sebestyén, 2021, British journal of haematology.

Serum β2-microglobulin measured by immunonephelometry: expression patterns and reference intervals in healthy adults

T. Masszi, Z. Szabó, Z. Mátrai, 2009, Clinical chemistry and laboratory medicine.

Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin.

L. Szekely, S. Eksborg, N. Nagy, 2010, Experimental hematology.

Identification of prognostic factors for plerixafor‐based hematopoietic stem cell mobilization

W. Wiktor-Jedrzejczak, G. Basak, B. Labar, 2011, American journal of hematology.

Retrospective Survey on the Prevalence and Outcome of Prior Autoimmune Diseases in Patients with Aplastic Anemia Reported to the Registry of the European Group for Blood and Marrow Transplantation

E. Lanino, A. Wåhlin, J. Passweg, 2010, Acta Haematologica.

Skin‐homing CD8+ T cells preferentially express GPI‐anchored peptidase inhibitor 16, an inhibitor of cathepsin K

E. Buzás, B. Érsek, E. Lajkó, 2018, European journal of immunology.

Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

S. Montoto, E. González-Barca, D. Blaise, 2019, Bone Marrow Transplantation.

Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

N. Kröger, S. Iacobelli, N. Russell, 2019, Bone Marrow Transplantation.

Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma

A. Tordai, L. Homolya, T. Masszi, 2017, Clinical lymphoma, myeloma & leukemia.

NFKB1 −94ins/delATTG polymorphism is a novel prognostic marker in first line‐treated multiple myeloma

A. Tordai, T. Masszi, H. Andrikovics, 2015, British journal of haematology.

Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia

N. Kröger, M. Robin, I. Yakoub-Agha, 2019, British journal of haematology.

Final Results of a Prospective Randomized Multicenter Phase III Trial Comparing Treosulfan/Fludarabine to Reduced Intensity Conditioning with Busulfan/Fludarabine Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Elderly or Comorbid Patients with Acute Myeloid Leukemia or Myelodysplasti

P. Dreger, C. Junghanss, F. Ciceri, 2017 .

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment

A. Palumbo, A. Jakubowiak, R. Hájek, 2017, Blood Cancer Journal.

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up

R. Greil, R. Hájek, B. Paiva, 2015, British journal of haematology.

Haematopoietic stem cell mobilization with plerixafor and G‐CSF in patients with multiple myeloma transplanted with autologous stem cells

W. Wiktor-Jedrzejczak, G. Basak, B. Labar, 2011, European journal of haematology.

Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial.

R. Greil, R. Hájek, H. Ludwig, 2009 .

High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte‐predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation‐lymphoma working party

S. Montoto, R. Malladi, F. Ferrara, 2018, American journal of hematology.

Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms.

N. Nagy, D. Alpár, Z. Borbényi, 2018, Leukemia research.

Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it’s not too late

W. Wiktor-Jedrzejczak, G. Basak, B. Labar, 2011, Leukemia & lymphoma.

Quality of life and its socio‐demographic and psychological determinants after bone marrow transplantation

G. Ungvari, T. Masszi, P. Reményi, 2013, European journal of haematology.

Coexistence of aortic valve stenosis and cardiac amyloidosis: echocardiographic and clinical significance

Z. Prohászka, T. Masszi, A. Apor, 2019, Cardiovascular Ultrasound.

Drugs, gene transfer, signaling factors: a bench to bedside approach to myocardial stem cell therapy

T. Símor, T. Masszi, S. Lueff, 2008, Heart Failure Reviews.

PNPLA3 rs738409 risk genotype decouples TyG index from HOMA2-IR and intrahepatic lipid content

A. Somogyi, T. Masszi, G. Firneisz, 2023, Cardiovascular Diabetology.

Complement lectin pathway activation is associated with COVID-19 disease severity, independent of MBL2 genotype subgroups

P. Lyons, Á. Szilágyi, Z. Prohászka, 2023, Frontiers in Immunology.

Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis

T. Masszi, F. Nicolini, N. Gallagher, 2012, Leukemia & lymphoma.

CIDP cured by allogeneic hematopoietic stem cell transplantation

Z. Borbényi, L. Siklós, T. Masszi, 2007, European journal of neurology.

[Stem cell transplantation in the imatinib era].

T. Masszi, 2005, Orvosi hetilap.

Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax

R. Szász, D. Alpár, Z. Pauker, 2023, International journal of molecular sciences.

Extramedullary Myeloid Sarcoma With Eosinophilia and FIP1L1-Pdgfra Rearrangement: Complete Cytogenetic Response To Imatinib Therapy

A. Tordai, T. Masszi, H. Andrikovics, 2013 .

Clinical Activity of Bosutinib by Mutational Status In Patients with Previously Treated Philadelphia Chromosome–positive Leukemias.

T. Brümmendorf, G. Martinelli, J. Cortes, 2010 .

Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib: Results from the ENESTFreedom study.

J. Radich, W. Wiktor-Jedrzejczak, F. Giles, 2016 .

Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial

M. Griesshammer, S. Verstovsek, R. Mesa, 2014 .

Safety of omacetaxine mepesuccinate (OM) subcutaneous (SQ) injection for the treatment of chronic myeloid leukemia (CML) patients (pts) resistant or intolerant to tyrosine kinase inhibitors (TKIs): Analysis of two phase II studies.

M. Baccarani, J. Cortes, J. Lipton, 2010 .

Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

P. Ganly, J. Laubach, P. Richardson, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial

A. Vannucchi, A. Tefferi, C. Harrison, 2020 .

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR4.5: Results from ENESTfreedom

J. Radich, F. Giles, G. Saglio, 2020 .

Treatment-free remission (TFR) following frontline (1L) nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): 192-week data from the ENESTfreedom study.

J. Radich, S. Acharyya, F. Giles, 2019, Journal of Clinical Oncology.

Clinical Characteristics of JAK2 V617F Mutation Positive Acute Myeloid Leukemia.

T. Masszi, H. Andrikovics, Z. Mátrai, 2006 .

Serum α2-HS glycoprotein concentration in patients with hematological malignancies

L. Kalabay, T. Masszi, K. Cseh, 1991, Annals of Hematology.

Associations between the von Willebrand Factor—ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality

Z. Prohászka, L. Cervenak, T. Masszi, 2022, Thrombosis and haemostasis.

Decreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients

P. Ferdinandy, B. Merkely, Z. Prohászka, 2022, Biomarkers in medicine.

P. Sonneveld, A. Nooka, T. Renaud, 2021, British journal of haematology.

Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients

Á. Illés, Z. Borbényi, T. Masszi, 2019, International Journal of Hematology.

European results of unrelated cord blood transplants

F. Locatelli, A. Nagler, P. Veys, 1998 .

Identification of the best‐suited donor for generating virus‐specific T cells

J. Sinko, T. Masszi, P. Reményi, 2020, Vox sanguinis.

Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391).

M. Dimopoulos, A. Jakubowiak, D. Siegel, 2016 .

Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime

Á. Illés, T. Masszi, G. Mikala, 2021, Orvosi hetilap.

Real World Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program

Á. Illés, T. Masszi, Á. Bátai, 2017 .

Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)

D. Esseltine, P. Ganly, N. Munshi, 2016 .

Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1.

P. Richardson, P. Moreau, Jianchang Lin, 2016 .

Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

A. Palumbo, A. Hui, P. Ganly, 2015 .

Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391)

Michael L. Wang, M. Dimopoulos, A. Palumbo, 2015 .

Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma

A. Nademanee, J. Radford, S. Ramsey, 2016, British journal of haematology.

Serum alpha 2-HS glycoprotein concentration in patients with hematological malignancies. A follow-up study.

L. Kalabay, T. Masszi, K. Cseh, 1991, Annals of hematology.

LBA28CARFILZOMIB (K) VS LOW-DOSE CORTICOSTEROIDS AND OPTIONAL CYCLOPHOSPHAMIDE (CY) IN PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 3 STUDY (FOCUS)

M. Dimopoulos, A. Palumbo, J. Miguel, 2014 .

Usefulness of a Novel Electrocardiographic Score to Estimate the Pre-Test Probability of Acute Pulmonary Embolism.

G. Katona, T. Masszi, G. Szénási, 2020, The American journal of cardiology.

The Aethera Trial: An Ongoing Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant

P. Stiff, T. Masszi, J. Walewski, 2014 .

Serum fetuin-A is decreased in cirrhotic patients with Wilson’s disease

L. Kalabay, T. Masszi, F. Szalay, 2023, PloS one.

Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391).

M. Dimopoulos, A. Jakubowiak, D. Siegel, 2015 .

Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.

D. Esseltine, P. Ganly, J. Miguel, 2016 .

Haematopoietic stem cell transplantation in children in eastern European countries 1985–2004: development, recent activity and role of the EBMT/ESH Outreach Programme

G. Dini, M. Labopin, J. Wachowiak, 2008, Bone Marrow Transplantation.

Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)

J. Cortes, R. Mesa, A. Vannucchi, 2013 .

Lymphoid aggregates may contribute to the migration and epithelial commitment of bone marrow-derived cells in colonic mucosa

B. Molnár, F. Sipos, Z. Tulassay, 2011, Journal of Clinical Pathology.

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib

E. Vellenga, H. Kantarjian, J. Cortes, 2012 .

A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM).

A. Jakubowiak, D. Siegel, P. Moreau, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM-3.

M. Dimopoulos, M. Matsumoto, T. Masszi, 2023, Journal of Clinical Oncology.

Challenges and potential in regenerative medicine: A joint report from EASAC and FEAM

C. Mummery, H. Einsele, J. Larghero, 2020 .

[Epidemiology of early infections after autologous hematopoietic stem cell transplantation. Analysis of data from 699 patients treated in a Hungarian centre].

J. Sinko, T. Masszi, P. Reményi, 2020, Orvosi hetilap.